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 Clinical Advisory 
Pre-Exposure Prophylaxis for HIV Infection 
Using Truvada
®
 (emtricitabine/tenofovir disoproxil fumarate) 
Updated: July 2013 
 
On June 14, 2013, the U.S. Centers for Disease Control and Prevention (CDC) published an update to the Interim 
Guidance for Pre-Exposure Prophylaxis (PrEP).  The CDC now recommends that PrEP be considered as one of 
several prevention options for persons at very high risk for HIV acquisition, including injecting drug users 
(IDUs).
1
 The updated Interim Guidance is available on the Morbidity and Mortality Weekly Report website.  
A previous version of this clinical advisory communicated the support of the Massachusetts Department of 
Public Health (MDPH) for use of Truvada
® 
as PrEP in certain circumstances for HIV-uninfected individuals at 
high risk of sexually acquired HIV infection. Consistent with the CDC’s recommendation, the MDPH supports 
the use of Truvada
®
 for PrEP for HIV-uninfected injecting drug users. This clinical advisory has been revised to 
reflect the use of Truvada for PrEP in this population.  
Background 
On July 16, 2012, the Food and Drug Administration (FDA) approved the use of Truvada
®2
 for pre-exposure 
prophylaxis (PrEP) for HIV-uninfected individuals at high risk of sexually acquired HIV infection. Truvada
®
 
(TDF/FTC) is an oral, antiretroviral combination medication that has been approved for the treatment of HIV 
infection since 2004.  Truvada
®
 PrEP offers an evidence-based approach to preventing the acquisition of HIV 
infection in certain circumstances, and should be considered when those circumstances are present.  This clinical 
advisory provides background on PrEP, evidence of the efficacy of Truvada
®
 as PrEP, guidelines for appropriate 
use, and sources of further information. 
Clinical Trials
3
  
Clinical trials in several populations have demonstrated efficacy of Truvada
®
 as pre-exposure prophylaxis to 
prevent HIV acquisition in HIV-uninfected individuals when combined with counseling about safer sex and other 
risk reduction methods. In the five clinical trials identified below and described in the table, resistance to FTC 
and Truvada
®
 was observed in some participants who were unknown to be acutely HIV infected upon initiation 
or who seroconverted during the trial.  Therefore, the potential for HIV drug resistance in persons taking PrEP 
does exist if acute HIV infection is not ruled out on initiation of PrEP or in cases of PrEP failure, which is most 
likely due to poor adherence.  Poor adherence makes selection of resistant viral strains more likely.  Clinical 
trials included:  
iPrEx4 - a randomized double-blind placebo-controlled multinational study evaluating Truvada
®
.  All subjects 
received monthly HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted 
infections (STI).  The Truvada
®
 group achieved a 42% (95% CI: 18% to 60%) reduction of HIV infection as 
compared to the placebo group.   
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Partners PrEP5 - a randomized, double-blind, placebo-controlled three-arm trial conducted in Kenya and Uganda 
to evaluate the efficacy and safety of TDF alone and Truvada
®
 versus placebo in preventing HIV acquisition by 
the uninfected partner. The risk reduction for Truvada
®
 relative to placebo was 75% (95% CI: 55% to 87%). 
TDF26 - a randomized, double-blind, placebo-controlled trial conducted in Botswana with low retention.  All 
subjects received counseling for risk reduction, screening and treatment for STI, and monitoring for adverse 
events.  Overall efficacy was 62% (95% CI: 22% to 83%); however, efficacy was not statistically significant in 
women. 
Fem-PrEP7 - a randomized, double-blind, placebo-controlled trial of Truvada
®
 combined with counseling  in 
Kenya, South Africa, and Tanzania, which  failed to reduce the rate of HIV infection. Inadequate adherence 
seems to have undermined the trial’s ability to assess efficacy. 
Bangkok Tenofivir Study
8
 – a randomized, double-blind, placebo-controlled trial conducted to determine the 
safety and efficacy of tenofovir disoproxil fumarate (TDF) in preventing HIV acquisition among IDUs in 
Bangkok, Thailand.  All subjects received HIV testing, risk reduction counseling, hepatitis B vaccine, monitoring 
for adverse events, and were offered methadone treatment, condoms, and bleach to clean injection equipment.  
Female participants were provided with contraceptives. Directly observed therapy (DOT) was available to 
participants. TDF decreased the risk of HIV infection by 49% (95% CI: 10% -72%). 
Clinical Trials:  Truvada
®
 as pre-exposure prophylaxis to prevent HIV acquisition 
Study Population No. and sex of 
participants 
mITT* % reduction in HIV incidence  
(95% CI) 
TDF blood 
detection† (95% 
CI) 
iPrEx Men who have 
sex with men 
2,499  
(100% male) 
42% (18%–60%) 92%  
(40%–99%) 
 All Men Women  
Partners 
PrEP 
Heterosexual 
HIV-
discordant 
couples 
4,758 couples 
(38% with 
female HIV+ 
partner) 
75%    
(55%–87%) 
84%    
(54%–95%) 
66%            
(28%–84%) 
90%  
(58%–98%) 
TDF2 Heterosexual 
men and 
women 
1,216  
(46% female) 
62%    
(22%–83%) 
80%    
(25%–97%) 
49%                   
(-21%–81%, NS)  
84%  
(-62%–98%, NS) 
FEM-
PrEP 
Heterosexual 
women 
2,056  
(100% female) 
NS NS NS NS 
Bangkok 
Tenofivir 
Study 
Injecting drug 
using men and 
women 
2,413  
(20% female) 
49%  
(10-72%) 
38%  
(-18-68%) 
79%  
(17-97%) 
70%  
(2% - 91%) 
Abbreviations: mITT = modified intent to treat analysis; CI = confidence interval; NS = finding not statistically significant. 
*Excluded only those enrolled participants later found to be infected at randomization and those with no follow-up visit or  
HIV test. 
†The percentage of reduction in HIV incidence among persons with TDF detected in blood, compared with those without detectable 
TDF. 
 
 
 
 
Important Considerations 
In determining the appropriateness of Truvada
®
 as PrEP, the following points should be considered: 
• In the absence of an HIV prevention vaccine, Truvada® as PrEP presents an evidence-based prevention 
option for individuals at high risk of sexual and drug-injection associated acquisition of HIV infection.
9
 
• In all of the trials, Truvada® was only one part of a multi-component intervention.  Truvada® was combined 
with relatively intensive, standard behavioral interventions, including risk reduction counseling, condom 
distribution, frequent HIV and STI testing, prompt STI treatment for newly diagnosed infections, and partner 
services. In the Bangkok Tenofovir Study, IDUs were provided with bleach to clean drug injection 
equipment and were offered methadone treatment.  
• All but one of the published studies were done in the developing world.  The iPrEx trial included men who 
have sex with men (MSM) and transgender women who have sex with men from the United States along 
with subjects at similar risk from five other countries. 
• All available data on efficacy of PrEP are from clinical trials.  Experience outside of a research environment 
is not available to assess effectiveness in the "real world." 
• Adherence to therapy, with adequate blood/tissue levels of active antiviral agents, appears to be the most 
important determinant of efficacy of Truvada
®
 as PrEP. 
• While Truvada® combined with other antiviral medications is well tolerated in patients being treated for HIV 
infection, the clinical trials reported variable, but in some instances not insignificant, levels of nausea, 
vomiting, and dizziness (particularly during the initiation phase), as well as some evidence of diminished 
bone density, serum creatinine changes and abnormal hepatic transaminase values.  Adverse events in long 
term administration of Truvada
®
 in HIV-uninfected individuals have not been fully assessed. 
• Among serodiscordant sexual partners, a protection rate of 92- 96% has been demonstrated for the HIV-
uninfected partner when the HIV-positive partner is treated early, and effectively with highly active 
antiretroviral therapy.
10,11
  Thus, "treatment as prevention" may be the best option for stable discordant 
partnerships. 
Initiating PrEP 
Research studies demonstrating efficacy of oral PrEP have involved particular high-risk populations, 
concomitant standardized behavioral interventions, fairly intensive support services, and use of Truvada
®
.  
Generalizability to other and broader population groups needs further assessment.  Use of other antiviral 
regimens for PrEP cannot be recommended. 
In light of the data available from clinical trials and the considerations above, the Massachusetts Department of 
Public Health (MDPH) identifies certain high risk individuals who may particularly benefit from PrEP and who 
should be evaluated for their risk for HIV acquisition, as well as readiness and clinical eligibility for PrEP.   
PrEP should only be prescribed for persons who are confirmed to be HIV-unifected and: 
• Are men who have sex with men (MSM) who currently have repeated unprotected anal and/or vaginal sex  
• Are transgender females who currently have repeated unprotected anal and/or vaginal sex  
• Are part of a heterosexual, serodiscordant couple wishing to conceive and have been educated about the 
potential risks/benefits
12
  
• Are injecting drug users who are at risk for HIV acquisition through blood exposure secondary to sharing 
injection equipment 
• Use “club drugs” in combination with unprotected sex 
• Engage in commercial sex work 
• Have recent or repeated diagnoses of syphilis, rectal gonorrhea or rectal chlamydia infection 
• Are otherwise deemed appropriate by the prescribing clinician 
 
  
Once a candidate for PrEP is confirmed at high risk of HIV infection:  
• HIV infection should be ruled out by HIV antibody/antigen testing using a 4th generation HIV assay, 
and/or an HIV RNA test.
13
   
• If signs and symptoms suggestive of acute HIV infection are present, rule out acute infection using an 
RNA test.
14
  PrEP should not be initiated until results of this testing is known.   
• The PrEP candidate should be screened for STI and viral hepatitis, and immunized against hepatitis A 
and B (treat chronic hepatitis B if indicated). 
• Possible drug interactions should be ruled out.15 
• Female candidates should be tested for pregnancy. If a patient takes PrEP while pregnant, or becomes 
pregnant during use of PrEP, providers are encouraged to prospectively and anonymously submit 
information about the pregnancy to the Antiretroviral Use in Pregnancy Registry.
16
  
• Confirm creatinine clearance is greater than or equal to 60mL/min (Cockcroft-Gault formula)  
Truvada
®
 is excreted via the kidney, and increased drug levels can accumulate with renal impairment.  Renal 
impairment also has been reported with use of TDF.  PrEP is not recommended for individuals with creatinine 
clearance of <60 mL per minute, and all patients treated with Truvada
®
 should have renal function monitored 
three months after initiation and every six months thereafter while using the PrEP regimen. 
   
Recommended Protocol 
Tenofovir disoproxil fumarate (TDF) 300 mg plus emtricitabine (FTC) 200 mg, as one Truvada
® 
tablet, daily.  At 
this time, the MDPH does not recommend intermittent PrEP based on periodic risk behavior due to a lack of 
efficacy evidence, questions about the ability of most individuals to correctly anticipate their high-risk behaviors, 
and concern about the development of antiviral resistance. 
 
Follow-up and Discontinuation 
The CDC has provided guidance for clinicians on the use of PrEP, with detailed recommendations for follow-up 
of patients on PrEP.
Error! Bookmark not defined.,17,18
  These are:  
• Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex 
with Men;  
• Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of 
HIV Infection in Heterosexually Active Adults; and 
• Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: 
PrEP for Injecting Drug Users.  
Links to these documents are in the Additional Resources section.  
Key points for follow-up include ongoing risk reduction and PrEP adherence counseling and ongoing provision 
of condoms to support sexual risk reduction.  Drug injectors should have access to sterile injection equipment, 
naloxone to prevent overdose, and opioid replacement therapy and/or other drug treatment.   
• Every 2-3 months: 
o HIV antibody/antigen testing (4th generation) 
o Pregnancy testing for women 
o Evaluation of adherence and need for more intensive support services 
o Screening/treating for STIs and hepatitis C infection 
o Monitoring serum creatinine 3 months after initiation and every 6 months thereafter 
• Report adverse events to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch  
 
 
Key indications for discontinuation include:  
• If the patient tests positive for HIV infection or suspected acute infection 
• If the patient wishes to discontinue treatment 
• If the patient is clinically diagnosed with any medical condition or has an abnormal lab value 
inconsistent with the safe administration of Truvada
® 
as PrEP 
• If the patient expresses diminishing commitment to the treatment protocol 
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ADDITIONAL RESOURCES 
 
• Truvada® was approved by the FDA with a Risk Evaluation and Mitigation Strategy (REMS).  A detailed 
description of this strategy as well as a list of educational resources for health care professionals is available 
at https://www.truvadapreprems.com.   
• The CDC offers current PrEP information and links to additional resources at www.cdc.gov/hiv/prep 
including:    
• Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the 
Prevention of HIV Infection in Heterosexually Active Adults 
• Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who 
Have Sex with Men     
• Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV 
Infection: PrEP for Injecting Drug Users 
• Massachusetts Department of Public Health at www.mass.gov/dph/aids 
• Project Inform at   http://www.projectinform.org/prep/  
• U.S. Department of Health and Human Services Health Resources and Services Administration Guide to 
HIV/AIDS Clinical Care http://hab.hrsa.gov/deliverhivaidscare/clinicalguide11  
 
